九典制药（300705.SZ）7月29日在投资者互动平台表示，您好！公司的全资子公司汇阳信息暂无人工智 能、算力等相关业务。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：子公司汇阳信息能详细介绍下吗？有人工智能、算力 吗？ ...

Group 1 - The company, Jiutian Pharmaceutical, has responded to investor inquiries regarding its products for treating joint pain, which include Loxoprofen Sodium Gel Patches, Ketoprofen Gel Patches, Anti-inflammatory Pain Relief Plasters, and Ketoprofen Gel [1] - The company also offers antipyretic medications such as Loxoprofen Sodium Tablets and Loxoprofen Sodium Oral Solutions [1]

Group 1: Product Information - The price of Loxoprofen Sodium Gel Patch in local procurement is approximately [2] - The company believes that Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch complement each other in the market and do not compete directly [2] - Currently, the Loxoprofen Sodium Gel Patch is in the information submission phase for the 11th batch of centralized procurement [3] Group 2: R&D and Product Development - The company has six external preparations already on the market, including Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch [3] - Expected approvals in 2025 include Indomethacin Gel Patch and Flurbiprofen Gel Patch, while approvals in 2026 are anticipated for Ketoprofen Patch and others [3] Group 3: Marketing Strategy - The company focuses on continuous R&D investment to enrich its product matrix and leverage first-mover, scale, and cost advantages [3] Group 4: Financial Outlook - The company projects a revenue growth of 10-20% for 2025, with a similar expected increase in net profit [3] - There are risks associated with achieving these targets due to market conditions and industry policies, which may lead to uncertainties in forecasts [3]

Group 1: Company Overview and Strategy - The company has a complete industrial chain layout, enabling self-production of active pharmaceutical ingredients and key excipients, ensuring product quality while effectively controlling costs [2][5] - The company plans to increase investment in the outpatient market, which has become a new growth engine for performance [2] - The company maintains high investment in R&D to continuously innovate and expand its product line, particularly focusing on the "JiuYue" brand in the transdermal drug delivery field [2][3] Group 2: Market Response and Pricing Strategy - The company will actively respond to the impact of competitor product approvals by optimizing cost structures and enhancing innovation capabilities [2][4] - With the nationwide implementation of centralized drug procurement policies, drug prices are expected to decline, necessitating continuous strategic adjustments by pharmaceutical manufacturers [4] Group 3: Financial Projections - For 2025, the company expects a revenue growth of 10-20% year-on-year, with a similar increase in net profit after deducting non-recurring items [6][7] - The company's operational plans and sales forecasts are subject to market conditions and regulatory environments, indicating significant uncertainty [7] Group 4: M&A Strategy - The company will consider multiple directions for mergers and acquisitions, focusing on targets that align with its development strategy, enhance technological capabilities, and enrich its product pipeline [7]

Core Insights - The oral hypoglycemic drug market is expanding rapidly due to the increasing prevalence of diabetes globally, with an estimated 589 million patients aged 20-79 by 2024, projected to reach 853 million by 2050 [4][6] - China has the highest number of diabetes patients at 148 million, accounting for 25% of the global total, with a significant rise in prevalence over the past 30 years [4][6] - The market for oral hypoglycemic drugs in China is expected to reach approximately 36.1 billion yuan by 2024, driven by both foreign and domestic companies [10][18] Industry Overview - Oral hypoglycemic drugs can be categorized into those that promote insulin secretion and those that lower blood sugar through other mechanisms [2][4] - The main classes of oral hypoglycemic drugs include sulfonylureas, meglitinides, DPP-4 inhibitors, GLP-1 receptor agonists, biguanides, TZDs, alpha-glucosidase inhibitors, and SGLT2 inhibitors [2][12] Market Dynamics - The oral hypoglycemic drug market in China is dominated by foreign companies such as AstraZeneca, MSD, and Bayer, which collectively hold over 50% market share [18] - The market is experiencing a shift with the rise of domestic companies, as they continue to innovate and develop new products [18][20] Recent Trends - The national centralized procurement policy has significantly impacted the pricing and availability of oral hypoglycemic drugs, with average price reductions reaching 88.5% in recent procurement rounds [15][16] - There is a growing trend towards the development of combination therapies and new mechanism drugs, such as glucose kinase activators and PPAR agonists, which are expected to become mainstream in diabetes treatment [20][22] Future Outlook - The DPP-4 inhibitors market is anticipated to expand further as domestic manufacturers increase their market penetration, potentially altering the current dominance of imported and generic drugs [20]

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

Group 1: Company Advantages - The company has a complete industrial chain layout, allowing it to independently produce active pharmaceutical ingredients and key excipients, ensuring product quality while effectively controlling costs [2] - A full-channel coverage system has been established, particularly in the outpatient market, which has become a new engine for revenue growth [2] - Continuous high investment in R&D to innovate and expand the product line, with a focus on strengthening the "JiuYue" brand in the transdermal drug delivery field [2] Group 2: Product Expectations and Market Strategy - The ketoprofen gel patch was approved for market in 2023 and has entered the national medical insurance directory, being the first generic product in the domestic market [3] - The company is optimistic about the market prospects for the ketoprofen gel patch and has developed new sales strategies focusing on outpatient market resources and internal sales team assessments [3] Group 3: Financial Projections - The company expects a revenue growth of 10-20% year-on-year for 2025, with a similar growth forecast for net profit excluding non-recurring items [4] - There are risks associated with achieving these targets due to market conditions, operational environment, and industry policies, which may introduce significant uncertainties [4] Group 4: Product Development Progress - The indomethacin gel patch is currently undergoing supplementary data review, while the pepper and musk gel patch has completed supplementary research and is awaiting registration application [5] - Differences between the loxoprofen sodium gel patch and the anti-inflammatory plaster include active ingredients, indications, and prescription attributes, with loxoprofen being a prescription drug for musculoskeletal pain [6]

根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等有关 规定，回购期间公司应当在每个月的前三个交易日内披露截至上月末的回购进展 情况。现将公司回购进展情况公告如下： 一、回购公司股份的进展情况 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-053 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于 2025 年 2 月 17 日召开 第四届董事会第九次会议，审议通过了《关于回购公司股份方案的议案》，同意 公司通过集中竞价交易方式以自有资金和股票回购专项贷款资金回购部分社会 公众股份，用于后期实施股权激励计划。本次回购的资金总额不低于人民币 10,000 万元且不超过人民币 15,000 万元，回购价格不超过人民币 24.98 元/股， 实施期限为自董事会审议通过回购股份方案之日起 12 个月内。具体内容详见 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-052 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于公司获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局下发的《药品注册证书》。现将相关情况公告如下： 一、证书的主要内容 摩熵数据显示，聚普瑞锌颗粒 2021 年、2022 年和 2023 年，全国总销量分 别为 17,459 万元、16,227 万元和 15,366 万元。 截至本公告日，聚普瑞锌颗粒国内共有 4 家企业取得了药品注册证书，公司 为国内第 4 家通过或视同通过仿制药质量和疗效一致性评价的企业。该药品注册 证书的取得丰富了公司的产品管线，对进一步优化公司产品结构有着积极意义。 2、剂型：颗粒剂 3、规格：75mg 4、注册分类：化学药品 3 类 5、申请事项：药品注册（境内生产） 6、证书编号：2025S01895 三、风险提示 1、 ...

关于股东减持股份实施完毕的公告 股东熊英保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 湖南九典制药股份有限公司（以下简称"公司"）于 2025 年 3 月 27 日披露 《关于股东减持股份的预披露公告》（公告编号：2025-016），公司财务总监熊 英女士，计划以集中竞价方式减持本公司股份不超过 180,232 股（占本公司总股 本比例 0.0363%，占剔除公司回购专用账户中的股份数量后的比例为 0.0365%）。 近日，公司收到熊英女士出具的《股份减持计划实施进展告知函》，其减持 股份计划已实施完毕。现将相关情况公告如下： 一、股东的基本情况 湖南九典制药股份有限公司 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-051 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 1、股东减持股份情况 | 股东名称 | 减持方式 | 减持时间 | 减持均价（元/股） 减持股数（股） 减持比例（%） | | | | --- | ...